Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 321

1.

Comparison of Effects of Diet on Mammary Cancer: Efficacy of Various Preventive Agents and Metabolomic Changes of Different Diets and Agents.

Lubet RA, Beger RD, Miller MS, Luster J, Seifried HE, Grubbs CJ.

Cancer Prev Res (Phila). 2018 Dec;11(12):831-840. doi: 10.1158/1940-6207.CAPR-18-0116. Epub 2018 Nov 20.

PMID:
30459210
2.

[Corrigendum] Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models.

Lubet RA, Steele VE, Juliana MM, Bode A, Moeinpour F, Grubbs CJ.

Oncol Rep. 2019 Jan;41(1):718. doi: 10.3892/or.2018.6802. Epub 2018 Oct 17.

3.

Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression.

Lubet RA, Steele VE, Shoemaker RH, Grubbs CJ.

Cancer Prev Res (Phila). 2018 Oct;11(10):595-606. doi: 10.1158/1940-6207.CAPR-18-0084. Epub 2018 Jul 25. Review.

PMID:
30045934
4.

Airway brushing as a new experimental methodology to detect airway gene expression signatures in mouse lung squamous cell carcinoma.

Pan J, Xiong D, Zhang Q, Szabo E, Miller MS, Lubet RA, Wang Y, You M.

Sci Rep. 2018 Jun 11;8(1):8895. doi: 10.1038/s41598-018-26902-7.

5.

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.

Lubet RA, Steele VE, Juliana MM, Bode A, Moeinpour F, Grubbs CJ.

Oncol Rep. 2018 Sep;40(3):1545-1553. doi: 10.3892/or.2018.6313. Epub 2018 Mar 14.

PMID:
29565450
6.

Novel mutational landscapes and expression signatures of lung squamous cell carcinoma.

Xiong D, Pan J, Yin Y, Jiang H, Szabo E, Lubet RA, Wang Y, You M.

Oncotarget. 2017 Dec 27;9(7):7424-7441. doi: 10.18632/oncotarget.23716. eCollection 2018 Jan 26.

7.

Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine.

Pan J, Zhang Q, Sei S, Shoemaker RH, Lubet RA, Wang Y, You M.

Oncotarget. 2017 Aug 1;8(47):82689-82699. doi: 10.18632/oncotarget.19831. eCollection 2017 Oct 10.

8.

Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

Zhang Q, Li R, Chen X, Lee SB, Pan J, Xiong D, Hu J, Miller MS, Szabo E, Lubet RA, Wang Y, You M.

Oncotarget. 2017 Aug 2;8(42):72447-72456. doi: 10.18632/oncotarget.19785. eCollection 2017 Sep 22.

9.

Lack of chemopreventive efficacy of metformin in rodent models of urinary bladder, head and neck, and colon/intestine cancer.

Thompson MD, Lubet RA, Mccormick DL, Clapper ML, Bode AM, Juliana MM, Moeinpour F, Grubbs CJ.

Oncol Lett. 2017 Sep;14(3):3480-3486. doi: 10.3892/ol.2017.6632. Epub 2017 Jul 20.

10.

Pioglitazone-mediated reversal of elevated glucose metabolism in the airway epithelium of mouse lung adenocarcinomas.

Xiong D, Pan J, Zhang Q, Szabo E, Miller MS, Lubet RA, Wang Y, You M.

JCI Insight. 2017 Jul 6;2(13). pii: 94220. doi: 10.1172/jci.insight.94220. [Epub ahead of print]

11.

Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents.

Xiong D, Pan J, Zhang Q, Szabo E, Miller MS, Lubet RA, You M, Wang Y.

Oncotarget. 2017 Mar 21;8(12):18885-18900. doi: 10.18632/oncotarget.13806.

12.

5MeCDDO Blocks Metabolic Activation but not Progression of Breast, Intestine, and Tongue Cancers. Is Antioxidant Response Element a Prevention Target?

Lubet RA, Townsend R, Clapper ML, Juliana MM, Steele VE, McCormick DL, Grubbs CJ.

Cancer Prev Res (Phila). 2016 Jul;9(7):616-23. doi: 10.1158/1940-6207.CAPR-15-0294. Epub 2016 May 5.

13.

Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ.

McCormick DL, Horn TL, Johnson WD, Peng X, Lubet RA, Steele VE.

PLoS One. 2015 Oct 30;10(10):e0141849. doi: 10.1371/journal.pone.0141849. eCollection 2015.

14.

Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer.

Ebben JD, Lubet RA, Gad E, Disis ML, You M.

Mol Carcinog. 2016 Nov;55(11):1517-1525. doi: 10.1002/mc.22405. Epub 2015 Sep 7.

15.

Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy.

Lubet RA, Scheiman JM, Bode A, White J, Minasian L, Juliana MM, Boring DL, Steele VE, Grubbs CJ.

Cancer Prev Res (Phila). 2015 Apr;8(4):296-302. doi: 10.1158/1940-6207.CAPR-14-0347. Epub 2015 Mar 11.

16.

Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models.

Thompson MD, Grubbs CJ, Bode AM, Reid JM, McGovern R, Bernard PS, Stijleman IJ, Green JE, Bennett C, Juliana MM, Moeinpour F, Steele VE, Lubet RA.

Cancer Prev Res (Phila). 2015 Mar;8(3):231-9. doi: 10.1158/1940-6207.CAPR-14-0181-T. Epub 2015 Feb 13.

17.

Enhanced antitumor activity of 3-bromopyruvate in combination with rapamycin in vivo and in vitro.

Zhang Q, Pan J, Lubet RA, Komas SM, Kalyanaraman B, Wang Y, You M.

Cancer Prev Res (Phila). 2015 Apr;8(4):318-26. doi: 10.1158/1940-6207.CAPR-14-0142. Epub 2015 Feb 2.

18.

Src is a novel potential off-target of RXR agonists, 9-cis-UAB30 and Targretin, in human breast cancer cells.

Kim MS, Lim DY, Kim JE, Chen H, Lubet RA, Dong Z, Bode AM.

Mol Carcinog. 2015 Dec;54(12):1596-604. doi: 10.1002/mc.22232. Epub 2014 Oct 18.

19.

Honokiol inhibits lung tumorigenesis through inhibition of mitochondrial function.

Pan J, Zhang Q, Liu Q, Komas SM, Kalyanaraman B, Lubet RA, Wang Y, You M.

Cancer Prev Res (Phila). 2014 Nov;7(11):1149-59. doi: 10.1158/1940-6207.CAPR-14-0091. Epub 2014 Sep 22.

20.

Targeting the insulin-like growth factor-1 receptor by picropodophyllin for lung cancer chemoprevention.

Zhang Q, Pan J, Lubet RA, Wang Y, You M.

Mol Carcinog. 2015 Jun;54 Suppl 1:E129-37. doi: 10.1002/mc.22206. Epub 2014 Aug 27.

PMID:
25163779
21.

Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model.

Nicastro HL, Grubbs CJ, Margaret Juliana M, Bode AM, Kim MS, Lu Y, You M, Milne GL, Boring D, Steele VE, Lubet RA.

Cancer Prev Res (Phila). 2014 Feb;7(2):246-54. doi: 10.1158/1940-6207.CAPR-13-0164. Epub 2013 Dec 17.

22.

Transcriptomic analysis by RNA-seq reveals AP-1 pathway as key regulator that green tea may rely on to inhibit lung tumorigenesis.

Pan J, Zhang Q, Xiong D, Vedell P, Yan Y, Jiang H, Cui P, Ding F, Tichelaar JW, Wang Y, Lubet RA, You M.

Mol Carcinog. 2014 Jan;53(1):19-29. doi: 10.1002/mc.21941. Epub 2012 Jul 31.

PMID:
24343902
23.

Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K.

Kim MS, Kim JE, Lim DY, Huang Z, Chen H, Langfald A, Lubet RA, Grubbs CJ, Dong Z, Bode AM.

Cancer Prev Res (Phila). 2014 Feb;7(2):236-45. doi: 10.1158/1940-6207.CAPR-13-0288. Epub 2013 Dec 10.

24.

6-C-(E-phenylethenyl)-naringenin suppresses colorectal cancer growth by inhibiting cyclooxygenase-1.

Li H, Zhu F, Chen H, Cheng KW, Zykova T, Oi N, Lubet RA, Bode AM, Wang M, Dong Z.

Cancer Res. 2014 Jan 1;74(1):243-52. doi: 10.1158/0008-5472.CAN-13-2245. Epub 2013 Nov 12.

25.

A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease.

Disis ML, Gad E, Herendeen DR, Lai VP, Park KH, Cecil DL, O'Meara MM, Treuting PM, Lubet RA.

Cancer Prev Res (Phila). 2013 Dec;6(12):1273-82. doi: 10.1158/1940-6207.CAPR-13-0182. Epub 2013 Oct 23.

26.

Select dietary phytochemicals function as inhibitors of COX-1 but not COX-2.

Li H, Zhu F, Sun Y, Li B, Oi N, Chen H, Lubet RA, Bode AM, Dong Z.

PLoS One. 2013 Oct 3;8(10):e76452. doi: 10.1371/journal.pone.0076452. eCollection 2013.

27.

Quantitative receptor-based imaging of tumor proliferation with the sigma-2 ligand [(18)F]ISO-1.

Shoghi KI, Xu J, Su Y, He J, Rowland D, Yan Y, Garbow JR, Tu Z, Jones LA, Higashikubo R, Wheeler KT, Lubet RA, Mach RH, You M.

PLoS One. 2013 Sep 20;8(9):e74188. doi: 10.1371/journal.pone.0074188. eCollection 2013.

28.

Concordant effects of aromatase inhibitors on gene expression in ER+ Rat and human mammary cancers and modulation of the proteins coded by these genes.

Lu Y, You M, Ghazoui Z, Liu P, Vedell PT, Wen W, Bode AM, Grubbs CJ, Lubet RA.

Cancer Prev Res (Phila). 2013 Nov;6(11):1151-61. doi: 10.1158/1940-6207.CAPR-13-0126. Epub 2013 Sep 25.

29.

The chemopreventive efficacies of nonsteroidal anti-inflammatory drugs: the relationship of short-term biomarkers to long-term skin tumor outcome.

Mikulec CD, Rundhaug JE, Simper MS, Lubet RA, Fischer SM.

Cancer Prev Res (Phila). 2013 Jul;6(7):675-85. doi: 10.1158/1940-6207.CAPR-13-0064. Epub 2013 May 16.

30.

Discovery of the novel mTOR inhibitor and its antitumor activities in vitro and in vivo.

Xie H, Lee MH, Zhu F, Reddy K, Huang Z, Kim DJ, Li Y, Peng C, Lim DY, Kang S, Jung SK, Li X, Li H, Ma W, Lubet RA, Ding J, Bode AM, Dong Z.

Mol Cancer Ther. 2013 Jun;12(6):950-8. doi: 10.1158/1535-7163.MCT-12-1241. Epub 2013 Mar 27.

31.

Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis.

Lubet RA, Szabo E, Iwata KK, Gill SC, Tucker C, Bode A, Steele VE, Juliana MM, Nicastro HL, Grubbs CJ.

Cancer Prev Res (Phila). 2013 May;6(5):448-54. doi: 10.1158/1940-6207.CAPR-12-0322. Epub 2013 Mar 26.

32.

Identification of an Aurora kinase inhibitor specific for the Aurora B isoform.

Xie H, Lee MH, Zhu F, Reddy K, Peng C, Li Y, Lim DY, Kim DJ, Li X, Kang S, Li H, Ma W, Lubet RA, Ding J, Bode AM, Dong Z.

Cancer Res. 2013 Jan 15;73(2):716-24. doi: 10.1158/0008-5472.CAN-12-2784. Epub 2012 Nov 1.

33.

Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B.

Li X, Li H, Li S, Zhu F, Kim DJ, Xie H, Li Y, Nadas J, Oi N, Zykova TA, Yu DH, Lee MH, Kim MO, Wang L, Ma W, Lubet RA, Bode AM, Dong Z, Dong Z.

Carcinogenesis. 2012 Dec;33(12):2548-57. doi: 10.1093/carcin/bgs283. Epub 2012 Sep 7.

34.

Taxifolin suppresses UV-induced skin carcinogenesis by targeting EGFR and PI3K.

Oi N, Chen H, Ok Kim M, Lubet RA, Bode AM, Dong Z.

Cancer Prev Res (Phila). 2012 Sep;5(9):1103-14. doi: 10.1158/1940-6207.CAPR-11-0397. Epub 2012 Jul 17.

35.

Identification of mammalian target of rapamycin as a direct target of fenretinide both in vitro and in vivo.

Xie H, Zhu F, Huang Z, Lee MH, Kim DJ, Li X, Lim DY, Jung SK, Kang S, Li H, Reddy K, Wang L, Ma W, Lubet RA, Bode AM, Dong Z.

Carcinogenesis. 2012 Sep;33(9):1814-21. doi: 10.1093/carcin/bgs234. Epub 2012 Jul 12.

36.

Prediction of molecular targets of cancer preventing flavonoid compounds using computational methods.

Chen H, Yao K, Nadas J, Bode AM, Malakhova M, Oi N, Li H, Lubet RA, Dong Z.

PLoS One. 2012;7(5):e38261. doi: 10.1371/journal.pone.0038261. Epub 2012 May 31.

37.

Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients.

Román-Pérez E, Casbas-Hernández P, Pirone JR, Rein J, Carey LA, Lubet RA, Mani SA, Amos KD, Troester MA.

Breast Cancer Res. 2012 Mar 19;14(2):R51.

38.

Aerosolized 3-bromopyruvate inhibits lung tumorigenesis without causing liver toxicity.

Zhang Q, Pan J, North PE, Yang S, Lubet RA, Wang Y, You M.

Cancer Prev Res (Phila). 2012 May;5(5):717-25. doi: 10.1158/1940-6207.CAPR-11-0338. Epub 2012 Mar 8.

39.

Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.

Lubet RA, Clapper ML, McCormick DL, Pereira MA, Chang WC, Steele VE, Fischer SM, Juliana MM, Grubbs CJ.

Oncol Rep. 2012 May;27(5):1400-6. doi: 10.3892/or.2012.1673. Epub 2012 Feb 3.

PMID:
22307264
40.

Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin.

Pereira MA, Warner BM, Knobloch TJ, Weghorst CM, Lubet RA, Steele VE, Casto BC.

Int J Cancer. 2012 Sep 15;131(6):1277-86. doi: 10.1002/ijc.27395. Epub 2012 Jan 31.

41.

Chemopreventive effect of a mixture of Chinese Herbs (antitumor B) on chemically induced oral carcinogenesis.

Wang Y, Yao R, Gao S, Wen W, Du Y, Szabo E, Hu M, Lubet RA, You M.

Mol Carcinog. 2013 Jan;52(1):49-56. doi: 10.1002/mc.20877. Epub 2011 Nov 15.

PMID:
22086836
42.

Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G(2)/M arrest and apoptosis.

Li J, Zhu F, Lubet RA, De Luca A, Grubbs C, Ericson ME, D'Alessio A, Normanno N, Dong Z, Bode AM.

Mol Carcinog. 2013 Feb;52(2):134-43. doi: 10.1002/mc.21839. Epub 2011 Nov 15.

43.

Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer.

Lu Y, Liu P, Van den Bergh F, Zellmer V, James M, Wen W, Grubbs CJ, Lubet RA, You M.

Cancer Prev Res (Phila). 2012 Feb;5(2):248-59. doi: 10.1158/1940-6207.CAPR-10-0363. Epub 2011 Oct 7.

44.

Discovery of novel checkpoint kinase 1 inhibitors by virtual screening based on multiple crystal structures.

Li Y, Kim DJ, Ma W, Lubet RA, Bode AM, Dong Z.

J Chem Inf Model. 2011 Nov 28;51(11):2904-14. doi: 10.1021/ci200257b. Epub 2011 Oct 12.

45.

(3-Chloroacetyl)-indole, a novel allosteric AKT inhibitor, suppresses colon cancer growth in vitro and in vivo.

Kim DJ, Reddy K, Kim MO, Li Y, Nadas J, Cho YY, Kim JE, Shim JH, Song NR, Carper A, Lubet RA, Bode AM, Dong Z.

Cancer Prev Res (Phila). 2011 Nov;4(11):1842-51. doi: 10.1158/1940-6207.CAPR-11-0158. Epub 2011 Sep 1.

46.

Lapatinib, a preventive/therapeutic agent against mammary cancer, suppresses RTK-mediated signaling through multiple signaling pathways.

Li J, Cho YY, Langfald A, Carper A, Lubet RA, Grubbs CJ, Ericson ME, Bode AM.

Cancer Prev Res (Phila). 2011 Aug;4(8):1190-7. doi: 10.1158/1940-6207.CAPR-10-0330. Epub 2011 Jul 26.

47.

Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention.

Fischer SM, Hawk ET, Lubet RA.

Cancer Prev Res (Phila). 2011 Nov;4(11):1728-35. doi: 10.1158/1940-6207.CAPR-11-0166. Epub 2011 Jul 21. Review.

48.

Effects of 5,6-benzoflavone, indole-3-carbinol (I3C) and diindolylmethane (DIM) on chemically-induced mammary carcinogenesis: is DIM a substitute for I3C?

Lubet RA, Heckman BM, De Flora SL, Steele VE, Crowell JA, Juliana MM, Grubbs CJ.

Oncol Rep. 2011 Sep;26(3):731-6. doi: 10.3892/or.2011.1316. Epub 2011 May 23.

PMID:
21617870
49.

Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice.

Fu H, Zhang J, Pan J, Zhang Q, Lu Y, Wen W, Lubet RA, Szabo E, Chen R, Wang Y, Chen DR, You M.

Mol Carcinog. 2011 Dec;50(12):913-21. doi: 10.1002/mc.20751. Epub 2011 Mar 3.

50.

Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers.

Lubet RA, Lu Y, Bode AM, You M, Verney ZM, Steele VE, Townsend R, Juliana MM, Grubbs CJ.

Oncol Rep. 2011 May;25(5):1389-97. doi: 10.3892/or.2011.1200. Epub 2011 Mar 1.

PMID:
21369704

Supplemental Content

Loading ...
Support Center